

---

## Information and recommendations for paramedics and doctors at the site

---

- Patients exposed only to toluene vapor do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid toluene (boiling point 110.6°C, 231.1°F respectively) can secondarily contaminate rescue and medical personnel by direct contact or evaporation of Toluene.
  - Toluene is irritating (defatting) when it comes in contact with the eyes, skin, nose and throat and causes headache, nausea, vertigo, dizziness, weakness, disorientation, and unconsciousness. Central and peripheral neuropathy has been noted.
  - There is no antidote to be administered to counteract the effects of toluene. Treatment consists of supportive measures.
- 

### 1. Substance information

Toluene (C<sub>6</sub>H<sub>5</sub>-CH<sub>3</sub>), CAS 108-88-3

Synonyms: methyl benzene, phenyl methane

Toluene is, at room temperature, a clear, colorless liquid with a boiling point of 110.6°C, 231.1°F, respectively. Both vapor and liquid are potential fire and explosion hazards. Toluene has a aromatic odor and an odor threshold of 2.5-8 ppm. It is slightly soluble in water, and miscible with common organic solvents. Carbon monoxide may be released in a toluene fire.

Toluene is an organic solvent with a high evaporation rate primarily produced through refining of crude oil. It is used in the production of benzene, trinitrotoluene, nylon, plastics and polyurethanes.

### 2. Routes of exposure

#### *Inhalation*

**Most exposures occur by inhalation.** Toluene is readily absorbed by the respiratory tract.

#### *Skin/eye contact*

It is absorbed through the skin causing systemic effects.

#### *Ingestion*

Toluene is readily absorbed from the gastrointestinal tract. Ingestion is uncommon in occupational settings but may be aspirated.

### 3. Acute health effects

#### *Systemic*

**Toluene causes headache, nausea, vertigo, dizziness, weakness, disorientation, and unconsciousness.** Acute exposure to high concentrations may produce signs of upper respiratory irritation, followed by asphyxia, muscular weakness, cardiac arrhythmia, coma and death from respiratory paralysis. Central and peripheral neuropathy and alterations in liver enzymes have been noted after long-term exposure.

#### *Respiratory*

Toluene is irritating to the upper respiratory tract.

#### *Dermal*

Irritation of the skin may be caused by direct contact to liquid Toluene.

#### *Ocular*

Eye contact to vapor or liquid Toluene causes burning discomfort, spasmodic blinking or involuntary closing of the eyelids, redness, and tearing.

## B 2

### Dose-effect relationships

Dose-effect relationships are as follows:

<u>Toluene concentration</u>	<u>Effect</u>
2.5 - 8 ppm	- Odor threshold
50 ppm	- ACGIH TLV
50 - 100 ppm	- slight subjective complaints including headache, fatigue, difficulty in concentrating
100 ppm	- NIOSH REL
150 ppm	- NIOSH STEL
300 ppm	- AIHA ERPG-2
500 ppm	- NIOSH IDLH
800 ppm	- fatigue, difficulty in concentrating, sleepiness, drowsiness and vertigo
4,000 ppm	- dangerous to life within 1 hours
10,000 - 30,000 ppm	- dangerous to life within a few minutes

## 4. Actions

### *Rescuer self-protection*

**In response situations that involve exposure to potentially unsafe levels of toluene (see below), pressure-demand, self-contained breathing apparatus and chemical-protective clothing shall be worn.**

Patients whose clothing or skin is contaminated with Toluene can secondarily contaminate other people by direct contact or evaporation of Toluene.

### *Patient recovery*

Patients should be removed from the contaminated zone immediately. Patients who are unable to walk may be removed on backboards or stretchers; if these are not available, carefully remove/transport patients with appropriate action to a safe zone, taking into account your self-protection.

Immediate priorities must follow the "A, B, C's" (Airway, Breathing, Circulation) of resuscitation.

### *Decontamination*

Patients exposed to Toluene require decontamination.

Patients who are able and cooperative may assist with their own decontamination. If clothing is contaminated, remove and double-bag the clothing.

**Assure that exposed or irritated eyes have been irrigated with plain water or saline for at least 20 minutes.** If not, continue eye irrigation during other basic care and transport.

Remove contact lenses if present and easily removable without additional trauma to the eye.

**Assure that exposed skin and hair have been flushed with plain water for at least 15 minutes.** If not, continue flushing during other basic care and transport. Protect eyes during flushing of skin and hair.

Assure that following ingestion mouth was rinsed with plenty of water and afterwards charcoal as a slurry (240 ml water / 30 g charcoal) has been administered. Emesis not recommended.

### *Initial treatment*

Therapy will be empiric; there is no specific antidote to counteract the effects of Toluene.

Patients with an exposure concentration of 50-100 ppm or greater (for 15 minutes or more) and patients without available exposure measurements but suspected of being exposed to concentrations of 100 ppm or greater (for 15 minutes or more) should be transferred to a hospital/emergency department.

The following measures are recommended if exposure by inhalation is 50-100 ppm (for 15 minutes or more), if symptoms, e. g. eye irritation or

pulmonary symptoms have developed, or if no exposure concentration can be estimated but exposure has possibly occurred:

- **Administration of oxygen**
- **Administration of 8 puffs of beclomethasone (800 µg beclomethasone dipropionate) from a metered dose inhaler.**

**Patients with severe clinical respiratory symptoms (e.g. bronchospasms, stridor) should be treated as follows:**

a) Nebulization of adrenaline (epinephrine): 2 mg adrenaline (2 ml) with 3 ml NaCl 0.9% and inhale through a nebulizer mask.

b) Administration of a  $\beta$ 2-selective adrenoceptor agonist, e.g., four strokes of terbutaline or salbutamol or fenoterol (one stroke usually contains 0.25 mg of terbutaline sulfate; or 0.1 mg of salbutamol; or 0.2 mg of fenoterol); this may be repeated once after 10 minutes. Alternatively, 2.5 mg salbutamol and 0.5 mg atrovent may be administered by nebulizer mask.

If inhalation is not possible, administration of terbutaline sulfate (0.25 mg to 0.5 mg) subcutaneously or salbutamol (0.2 mg to 0.4 mg over 15 minutes) intravenously.

c) If (b) is not effective or sufficient: administration of theophylline (5 mg/kg body weight over 20 to 30 minutes).

d) Intravenous administration of 250 mg methylprednisolone (or equivalent steroid dose).

**Patients with clinical signs of a toxic lung edema (e.g. foamy sputum, wet crackles) should be treated as follows:**

a) Start CPAP-therapy (Continuous Positive Airway Pressure Ventilation).

b) Intravenous administration of 1000 mg methylprednisolone (or an equivalent steroid dose) is recommended.

**Intubation of the trachea or an alternative airway management should be considered in cases of respiratory compromise. When the patient's condition precludes this, consider cricothyrotomy if equipped and trained to do so.**

Note: Efficacy of corticosteroid administration has not yet been proven in controlled clinical studies.

If liquid Toluene has been in contact with the skin, irritations may result, treat as thermal burns.

After eye exposure, irritation may result; treat as thermal burns. Consult an ophthalmologist.

*Patient release/  
follow-up instructions*

**Asymptomatic patients** with an exposure concentration of **less than 50-100 ppm** (and less than 15 minutes) or minor direct contact to liquid Toluene **as well as patients who have no signs or symptoms of toxicity may be discharged after an appropriate observation period in the following circumstances:**

- a) The evaluating physician is experienced in the evaluation of individuals with Toluene exposure.
- b) Information and recommendations for patients with follow-up instructions are provided verbally and in writing. Patients are advised to seek medical care promptly if symptoms develop or recur.
- c) The physician is comfortable that the patient understands the health effects of Toluene and the provided follow-up instructions.
- d) Site medical is notified, so that the patient may be contacted at regular intervals in the 24-hour period following release.

- e) Drinking of alcohol beverages should be forbidden for at least 72 hours.
- f) Heavy physical work should be precluded for 24 hours.
- g) Exposure to cigarette smoke should be avoided for 72 hours; the smoke may worsen the condition of the lungs.

In this document BASF has made a diligent effort to ensure the accuracy and currency of the information presented but makes no claim that the document comprehensively addresses all possible situations related to this topic. This document is intended as an additional resource for paramedics and doctors at the site in assessing the condition and managing the treatment of patients exposed to toluene. It is not, however, a substitute for the professional judgement of a paramedic or a doctor and must be interpreted in the light of specific information regarding the patient available to such a paramedic or doctor and in conjunction with other sources of authority.

**BASF SE**  
Corporate Health Management  
Carl-Bosch-Straße 38  
67056 Ludwigshafen  
Germany

**BASF Corporation**  
Medical Department  
100 Campus Drive, M/S F 221  
Florham Park, NJ 07932  
USA